Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Transfusion. 2011 Nov;51(Suppl 4):87S–93S. doi: 10.1111/j.1537-2995.2011.03371.x

Figure 2. Enhanced tumor susceptibility and shortened survival in Hsal2 -deficient mice.

Figure 2

Survival curves of Hsal2−/− or +/−/p53−/− and Hsal2+/+/p53−/−. All mice died from aggressive T cell lymphoblastic lymphomas.